Diakonos Oncology
Clinical-stage biotechnology company developing autologous dendritic cell vaccines for difficult-to-treat solid tumors. The company’s approach uses a homologous antigen-loading strategy to engage a Th1 cytotoxic immune response. Active programs include clinical development in glioblastoma, pancreatic ductal adenocarcinoma, and refractory melanoma, with regulatory interactions including FDA Fast Track and Orphan Drug designations.
Industries
Nr. of Employees
small (1-50)
Products
Autologous dendritic cell vaccine platform
Personalized vaccines manufactured from a patient’s dendritic cells combined with amplified tumor mRNA and tumor-derived proteins to stimulate a Th1 cytotoxic immune response.
DOC1021
DOC1021 is a multi-step process that harnesses the patient’s natural immune response using dendritic cells stimulated by homologous antigenic loading to target and eliminate cancer cells.
Autologous Dendritic Cells Pancreatic Cancer Therapy
An investigational delivery of autologous Dendritic Cells (DCs) to pancreatic cancer patients as adjuvant therapy following completion of standard chemotherapy.
Diakonos Dendritic Cell Vaccine
An investigational personalized cancer immunotherapy utilizing a proprietary 'double-loading' mechanism of tumor mRNA and lysate onto dendritic cells to stimulate a robust Th1 anti-viral immune response and killer T cell activation.
Autologous dendritic cell vaccine platform
Personalized vaccines manufactured from a patient’s dendritic cells combined with amplified tumor mRNA and tumor-derived proteins to stimulate a Th1 cytotoxic immune response.
DOC1021
DOC1021 is a multi-step process that harnesses the patient’s natural immune response using dendritic cells stimulated by homologous antigenic loading to target and eliminate cancer cells.
Autologous Dendritic Cells Pancreatic Cancer Therapy
An investigational delivery of autologous Dendritic Cells (DCs) to pancreatic cancer patients as adjuvant therapy following completion of standard chemotherapy.
Diakonos Dendritic Cell Vaccine
An investigational personalized cancer immunotherapy utilizing a proprietary 'double-loading' mechanism of tumor mRNA and lysate onto dendritic cells to stimulate a robust Th1 anti-viral immune response and killer T cell activation.
Services
Design and execution of Phase I/II and randomized Phase II clinical trials in glioblastoma, pancreatic cancer, and refractory melanoma with academic and clinical site partners.
Partnerships for mechanistic studies, animal model validation and publication of immunological findings supporting clinical translation.
Manufacturing operations and process optimization for production of individualized autologous dendritic cell vaccines for clinical studies.
Design and execution of Phase I/II and randomized Phase II clinical trials in glioblastoma, pancreatic cancer, and refractory melanoma with academic and clinical site partners.
Partnerships for mechanistic studies, animal model validation and publication of immunological findings supporting clinical translation.
Manufacturing operations and process optimization for production of individualized autologous dendritic cell vaccines for clinical studies.
Expertise Areas
- Clinical trial management
- Dendritic cell immunotherapy
- Cell therapy manufacturing (CMC)
- Immunology mechanism discovery (Th1 polarization, MHC I/II antigen homology)
Key Technologies
- Autologous dendritic cell vaccine platform
- Homologous antigen loading (MHC I/II) for Th1 activation
- mRNA amplification from tumor tissue
- Electroporation-based mRNA delivery
News & Updates
Final closing of an $11.4 million seed financing round to advance clinical development and manufacturing readiness for the autologous dendritic cell vaccine platform.
FDA granted Fast Track designation for the dendritic cell vaccine programs in glioblastoma and pancreatic ductal adenocarcinoma.
FDA Fast Track designation awarded for the pancreatic ductal adenocarcinoma program; scientific advisory board expansion announced.
Received Orphan Drug designation from the FDA for malignant glioma, including glioblastoma multiforme.
Interim Phase 1 results reported increased 12-month overall survival among evaluable newly diagnosed glioblastoma patients compared to historical controls; data presented at AACR.
Presented Phase 1 interim analysis at the Congress of Neurological Surgeons showing 93% 12-month survival among evaluable newly diagnosed GBM patients in the study cohort.
Final closing of an $11.4 million seed financing round to advance clinical development and manufacturing readiness for the autologous dendritic cell vaccine platform.
FDA granted Fast Track designation for the dendritic cell vaccine programs in glioblastoma and pancreatic ductal adenocarcinoma.
FDA Fast Track designation awarded for the pancreatic ductal adenocarcinoma program; scientific advisory board expansion announced.
Received Orphan Drug designation from the FDA for malignant glioma, including glioblastoma multiforme.
Interim Phase 1 results reported increased 12-month overall survival among evaluable newly diagnosed glioblastoma patients compared to historical controls; data presented at AACR.
Presented Phase 1 interim analysis at the Congress of Neurological Surgeons showing 93% 12-month survival among evaluable newly diagnosed GBM patients in the study cohort.